NO912825L - Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper. - Google Patents

Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.

Info

Publication number
NO912825L
NO912825L NO91912825A NO912825A NO912825L NO 912825 L NO912825 L NO 912825L NO 91912825 A NO91912825 A NO 91912825A NO 912825 A NO912825 A NO 912825A NO 912825 L NO912825 L NO 912825L
Authority
NO
Norway
Prior art keywords
munogent
protein
procedure
preparation
anionic groups
Prior art date
Application number
NO91912825A
Other languages
English (en)
Norwegian (no)
Other versions
NO912825D0 (no
Inventor
William J Leanza
Stephen Marburg
Emilio A Emini
Richard L Tolman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO912825D0 publication Critical patent/NO912825D0/no
Publication of NO912825L publication Critical patent/NO912825L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO91912825A 1990-07-19 1991-07-18 Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper. NO912825L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55533990A 1990-07-19 1990-07-19
US55596690A 1990-07-19 1990-07-19
US71527691A 1991-06-19 1991-06-19
US71527891A 1991-06-19 1991-06-19

Publications (2)

Publication Number Publication Date
NO912825D0 NO912825D0 (no) 1991-07-18
NO912825L true NO912825L (no) 1992-01-20

Family

ID=27504782

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91912825A NO912825L (no) 1990-07-19 1991-07-18 Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.

Country Status (11)

Country Link
US (1) US5606030A (fr)
EP (1) EP0467700A3 (fr)
JP (1) JPH07113038B2 (fr)
KR (1) KR920002633A (fr)
AU (1) AU8113591A (fr)
CA (1) CA2047073A1 (fr)
FI (1) FI913476A (fr)
IE (1) IE912558A1 (fr)
IL (1) IL98845A0 (fr)
NO (1) NO912825L (fr)
PT (1) PT98380A (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047042A1 (fr) * 1990-07-19 1992-01-20 John Hannah Peptides cycliques neutralisant le vih
CA2047033A1 (fr) * 1990-07-19 1992-01-20 Elizabeth E. Sugg Peptides cycliques neutralisant le vih
CA2047078A1 (fr) * 1990-07-19 1992-01-20 Steven S. Bondy Peptides cycliques neutralisant le vih
CA2058876A1 (fr) * 1991-12-19 1993-06-20 Maria A. Bednarek Peptides cycliques, principaux determinants de neutralisation du vih
GB2271995A (en) * 1992-10-15 1994-05-04 Merck & Co Inc HIV peptide conjugated via anionic spacer to protein
GB2282380A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugate of epitopes of HIV with a protein complex from Neisseria
GB2282378A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugates of epitopes of HIV with a protein complex from Neisseria
US6664367B1 (en) * 1994-07-21 2003-12-16 Biosynthema, Inc. Stable analogs of bioactive peptides containing disulfide linkages
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
CA2338000C (fr) * 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives 4-thiomaleimidiques solubles dans l'eau et methodes pour les produire
DE19936715A1 (de) * 1999-08-06 2001-02-15 Ticona Gmbh Emissionsarme eingefärbte Polyoxymethylen-Formmassen
JP2004509846A (ja) * 2000-06-02 2004-04-02 メルク　エンド　カムパニー　インコーポレーテッド 肝炎ｃ型ウイルスコンジュゲート
EP1178317B1 (fr) 2000-07-24 2004-11-10 Health Research, Inc. Méthode de détection de l'antigène prostatique spécifique membranaire dans le sérum
US20030224011A1 (en) * 2001-05-29 2003-12-04 Conley Anthony J Hepatitis c virus conjugates
CA2508539A1 (fr) * 2002-12-03 2004-06-17 Sloan-Kettering Institute For Cancer Research Antigenes specifiques gp120, leurs conjugues, leur procedes de preparation et leur utilisation
US20060094017A1 (en) * 2003-02-14 2006-05-04 Conley Anthony J Immunogens for hiv vaccine
RU2005131016A (ru) * 2003-03-07 2006-06-10 Мерк энд Ко., Инк. (US) Вакцина вируса гриппа
DE602004031051D1 (de) * 2003-12-18 2011-02-24 Angeletti P Ist Richerche Bio Verfahren zur herstellung eines peptid-träger-konjugats mit hoher immunogenizität
EP1885395A4 (fr) * 2005-05-16 2009-12-02 Merck & Co Inc Procédé d'augmentation de l'immunigénicité des antigènes de plasmodium
WO2012065034A1 (fr) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Vaccins à base de conjugués de peptide énolase, contre staphylococcus aureus
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
KR102289985B1 (ko) 2014-12-08 2021-08-17 삼성디스플레이 주식회사 표시 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4762913A (en) * 1973-05-07 1988-08-09 The Ohio State University Antigenic modification of polypeptides
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4956273A (en) * 1985-10-24 1990-09-11 Southwest Foundation For Biomedical Research Synthetic peptides and method of use for diagnosis and vaccination for AIDS and ARC
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
JPH01500432A (ja) * 1986-07-21 1989-02-16 サウスウェスト・ファウンデーション・フォー・バイオメディカル・リサーチ Ａｉｄｓおよびａｒｃのウィルス原因物質に対して免疫化するための組成物および方法
EP0525828A3 (en) * 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
CA1329124C (fr) * 1987-02-02 1994-05-03 Jerald C. Sadoff Vaccin conjugue anti-malaria
AU1711888A (en) * 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
IL87391A0 (en) * 1987-08-27 1989-01-31 Repligen Corp Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
NL8702403A (nl) * 1987-10-09 1989-05-01 Stichting Centr Diergeneeskund Oligopeptiden en gebruik daarvan voor diagnostische en vaccinatiedoeleinden voor aids en arc.
EP0311228A3 (fr) * 1987-10-09 1990-05-02 Repligen Corporation Polypeptides recombinants et leur utilisation, y compris un diagnostic pour le virus du SIDA
JPH01190636A (ja) * 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
DE3802060A1 (de) * 1988-01-25 1989-07-27 Boehringer Mannheim Gmbh Hapten-protein-konjugate und ihre verwendung
CA1341285C (fr) * 1988-02-12 2001-08-14 Chang Yi Wang Peptides synthetiques servant a la detection d'anticorps de la proteine de surface gp120 du virus hiv, destines au diagnostic du sida, ainsi que d'etats pre-sidatiques, ou aux fins de vaccins
EP0339504A3 (fr) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
AU640619B2 (en) * 1988-10-03 1993-09-02 Repligen Corporation Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
IL94558A0 (en) * 1989-06-06 1991-03-10 Merck & Co Inc Conjugate immunogen for aids and vaccine and pharmaceutical compositions containing it
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
CA2047078A1 (fr) * 1990-07-19 1992-01-20 Steven S. Bondy Peptides cycliques neutralisant le vih
DE4033714C3 (de) * 1990-10-24 1995-09-07 Brahms Diagnostica Gmbh Neues Hapten-Analytikum basierend auf dem Prinzip einer Antigen-Antikörper-Reaktion

Also Published As

Publication number Publication date
FI913476A (fi) 1992-01-20
US5606030A (en) 1997-02-25
KR920002633A (ko) 1992-02-28
EP0467700A3 (en) 1993-03-10
FI913476A0 (fi) 1991-07-18
IL98845A0 (en) 1992-07-15
NO912825D0 (no) 1991-07-18
EP0467700A2 (fr) 1992-01-22
JPH0625300A (ja) 1994-02-01
IE912558A1 (en) 1992-01-29
PT98380A (pt) 1992-05-29
CA2047073A1 (fr) 1992-01-20
JPH07113038B2 (ja) 1995-12-06
AU8113591A (en) 1992-01-23

Similar Documents

Publication Publication Date Title
NO912825L (no) Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.
NO884795D0 (no) Rekombinant, humant immunoglobulin og fremgangsmaate for fremstilling av dette.
NL300249I2 (en) Cephalosporins and homologues, preparations and pharmaceutical preparations.
DK93388D0 (da) Lav-virusvarianter, dna- og proteinbestanddele deraf og anvendelse deraf, saerlig til diagnostiske formaal og til fremstilling af immunogene praeparater
NO894228D0 (no) Tienopyridiner, fremstilling, mellomprodukter og farmasoeytiske preparater.
NL8003762A (nl) Nieuwe tetra- of pentapeptiden, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze peptiden bevatten.
NO900577D0 (no) Cyklosporinholdige preparater og fremgangsmaate for deres fremstilling.
NO871025D0 (no) Polypeptid, dna og fremgangsmaate for fremstilling derav.
NO883834D0 (no) Fremgangsmaate for fremstilling av nye hiv-proteiner og peptider.
NO912271D0 (no) Somatostatinpreparater, deres fremstilling og anvendelse.
DK196687A (da) Kombineret vaccine, samt fremgangsmaade til fremstilling deraf
NO893794D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO901396L (no) Fytosanitaere preparater, deres fremstilling og deres anvendelse for behandling av kryptogame sykdommer.
NO884324D0 (no) Fremgangsmaate til fremstilling av reninhemmende peptider og deres anvendelse.
EP0311228A3 (fr) Polypeptides recombinants et leur utilisation, y compris un diagnostic pour le virus du SIDA
AU8976691A (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
NO911543L (no) Katalysatorsystem og fremgangsmaate for fremstilling av 1,2-diklorethan.
NO874106D0 (no) Anioniske kopolymerer, samt fremgangsmaate for fremstilling av slike, og anvendelse av kopolymerene.
NO891926L (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
AU2715288A (en) Human respiratory syncytialvirus vaccine derived from the 1a (9.5 kd) protein
ZA915626B (en) Coconjugate vaccines comprising immunogenic protein,hiv related peptides,and anionic moieties
AU1814792A (en) Immunogenic peptides or polypeptides of the bvd virus and related viruses, vaccines incorporating them or expressing them, methods and means of production thereof
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.
NO893796D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO912192L (no) Rekombinante dna og fremgangsmaate for fremstilling av chimere antistoffer.